The electrical current serves as a delivery aid rather than the cross-linking stimulus itself. It drives charged riboflavin molecules through the corneal epithelium, helping place the photosensitizer within the cornea before ultraviolet-A exposure. This separation of roles matters because riboflavin must be present before light activation can promote collagen cross-links in the stromal tissue.
Riboflavin and ultraviolet-A perform complementary functions in this protocol. Riboflavin absorbs the ultraviolet-A light and acts as the photosensitizer, while the resulting light-activated process promotes collagen cross-link formation in the stroma. The sequence therefore links delivery, light absorption, and tissue strengthening, rather than treating electrical exposure as the source of the cross-links.
Protocol parameters are central because they can alter how much riboflavin penetrates the cornea and how the treatment performs. They also bear on safety and clinical outcomes. For that reason, the electrical-delivery conditions and ultraviolet-A treatment conditions should be considered as an integrated protocol, since changes in either stage may affect the final strengthening response.
The workflow first uses low-current iontophoresis to enhance riboflavin delivery through the corneal epithelium. After riboflavin has been delivered, ultraviolet-A exposure activates the photosensitizer and promotes collagen cross-linking in the stroma. This sequence makes delivery precede irradiation and connects each procedural stage to its intended biological role.
The approach is being studied and applied for corneal ectatic conditions, including keratoconus and ectasia after refractive surgery. Its epithelium-on orientation may be desirable in selected situations, making it relevant when clinicians are evaluating ways to strengthen weakened corneal tissue while preserving that procedural feature.
Assessment should extend beyond whether riboflavin reaches the cornea. The protocol parameters can influence penetration, treatment effectiveness, safety, and clinical outcomes, so these dimensions need to be considered together. In medicine, that broader view helps distinguish adequate photosensitizer delivery from the overall success and safety of corneal strengthening.